Who
Morgan R. Brown
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Clene; Chief Financial Officer, Lipocine; Officer, Innovus Pharmaceuticals; Executive VP, World Heart; Vice President, Finance, Nps Pharmaceuticals.
In numbers
- Trades disclosed
- 55
- Buys
- 0
- Sells
- 4
- Bought
- $0
- Sold
- $55K
- Companies
- 5
- Companies where not an officer
- 0
- First trade
- 17 Jan 2006
- Last trade
- 11 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 15 Jun 2026 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 22 Jan 2026filed 23 Jan 2026 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 22 Jan 2026filed 23 Jan 2026 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 25 Sep 2025filed 29 Sep 2025 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 18 Sep 2025filed 19 Sep 2025 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 24 Feb 2025filed 25 Feb 2025 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 16 Aug 2024filed 19 Aug 2024 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 7 Jun 2024filed 11 Jun 2024 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —400,000 at $0.00 | filing |
| 7 Jun 2024filed 11 Jun 2024 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —600,000 at $0.00 | filing |
| 29 Jun 2023filed 3 Jul 2023 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —400,000 at $0.00 | filing |
| 17 Feb 2023filed 21 Feb 2023 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 4 Nov 2022filed 7 Nov 2022 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 1 Feb 2022filed 3 Feb 2022 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 7 Dec 2021filed 8 Dec 2021 | LPCN Lipocineoption or derivative · Biotechnology | SEC FORM 4 Code A | $197K176,000 at $1.12 | filing |
| 16 Dec 2020filed 17 Dec 2020 | LPCN Lipocineoption or derivative · Biotechnology | SEC FORM 4 Code M | —28,125 at $0.00 | filing |
| 16 Dec 2020filed 17 Dec 2020 | LPCN LipocineBiotechnology | SEC FORM 4 Code M | —28,125 at $0.00 | filing |
| 16 Dec 2020filed 17 Dec 2020 | LPCN LipocineBiotechnology | SEC FORM 4 Sold | $11K8,437 at $1.35 | filing |
| 15 Dec 2020filed 17 Dec 2020 | LPCN Lipocineoption or derivative · Biotechnology | SEC FORM 4 Code A | $219K160,000 at $1.37 | filing |
| 5 Dec 2020filed 8 Dec 2020 | LPCN Lipocineoption or derivative · Biotechnology | SEC FORM 4 Code M | —70,754 at $0.00 | filing |
News
Lipocine (NASDAQ:LPCN) & Harmony Biosciences (NASDAQ:HRMY) Head-To-Head AnalysisLPCN · dailypolitical.com · 14 Oct 2026Lipocine (NASDAQ: LPCN) wins Health Canada approval for TLANDO in CanadaLPCN · tickerreport.com · 7 Oct 2026
0 headlines in the last 90 days name Morgan R. Brown; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.